FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

J. David Port

Research Profile

Chemicals & Drugs

Anatomy

Myocardium

Disorders

Living Beings

Cricetinae

Physiology

Co-author Network

Publications

TOP 3
J. David Port; Carmen Sucharov
Role of microRNAs in cardiovascular disease: therapeutic challenges and potentials.
Michael R Bristow; Guinevere A Murphy; Heidi Krause-Steinrauf; Jeffrey L Anderson; John F Carlquist; Surai Thaneemit; Vaishali Krishnan; William T Abraham; Brian D Lowes; J. David Port; Gordon W Davis; Laura C Lazzeroni; Alastair D Robertson; Phillip W Lavori; Stephen B Liggett
An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure.
Carmen Sucharov; Michael R Bristow; J. David Port
miRNA expression in the failing human heart: functional correlates.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of J. David Port (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: J. David Port; Carmen Sucharov
Role of microRNAs in cardiovascular disease: therapeutic challenges and potentials.
Journal of cardiovascular pharmacology 2010;56(5):444-53.
2010: Michael R Bristow; Guinevere A Murphy; Heidi Krause-Steinrauf; Jeffrey L Anderson; John F Carlquist; Surai Thaneemit; Vaishali Krishnan; William T Abraham; Brian D Lowes; J. David Port; Gordon W Davis; Laura C Lazzeroni; Alastair D Robertson; Phillip W Lavori; Stephen B Liggett
An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure.
Circulation. Heart failure 2010;3(1):21-8.
2008: Carmen Sucharov; Michael R Bristow; J. David Port
miRNA expression in the failing human heart: functional correlates.
Journal of molecular and cellular cardiology 2008;45(2):185-92.
2008: Aldo Pende; Lidia Contini; Raffaella Sallo; Mario Passalacqua; Rasheeda Tanveer; J. David Port; G Lotti
Characterization of RNA-binding proteins possibly involved in modulating human AT 1 receptor mRNA stability.
Cell biochemistry and function 2008;26(4):493-501.
2007: Rebekah S Vest; Kurtis D Davies; Heather O'Leary; J. David Port; K Ulrich Bayer
Dual mechanism of a natural CaMKII inhibitor.
Molecular biology of the cell 2007;18(12):5024-33.
2007: Pamela S David; Rasheeda Tanveer; J. David Port
FRET-detectable interactions between the ARE binding proteins, HuR and p37AUF1.
RNA (New York, N.Y.) 2007;13(9):1453-68.
2006: Stephen B Liggett; Jeanne Mialet Perez; Surai Thaneemit; Stewart A Weber; Scott M Greene; Danielle Hodne; Bradley Nelson; Jennifer Morrison; Michael J Domanski; Lynne E Wagoner; William T Abraham; Jeffrey L Anderson; John F Carlquist; Heidi Krause-Steinrauf; Laura C Lazzeroni; J. David Port; Philip W Lavori; Michael R Bristow
A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(30):11288-93.
2004: Laura K Zerbe; Irene Pino; Ruben Pio; Pippa F Cosper; Lori D Dwyer-Nield; Amy M Meyer; J. David Port; Luis M Montuenga; Alvin M Malkinson
Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing.
Molecular carcinogenesis 2004;41(4):187-96.
2004: Violetta V Headley; Rasheeda Tanveer; Scott M Greene; Adam Zweifach; J. David Port
Reciprocal regulation of beta-adrenergic receptor mRNA stability by mitogen activated protein kinase activation and inhibition.
Molecular and cellular biochemistry 2004;258(1-2):109-19.
2002: Catherine Communal; Wilson S Colucci; Andrea Remondino; Douglas B Sawyer; J. David Port; Scott E Wichman; Michael R Bristow; Krishna Singh
Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium.
Journal of cardiac failure 2002;8(2):86-92.
2002: Burns C Blaxall; Aldo Pende; Steven C Wu; J. David Port
Correlation between intrinsic mRNA stability and the affinity of AUF1 (hnRNP D) and HuR for A+U-rich mRNAs.
Molecular and cellular biochemistry 2002;232(1-2):1-11.
2001: J. David Port; Michael R Bristow
beta-Adrenergic receptors, transgenic mice, and pharmacological model systems.
Molecular pharmacology 2001;60(4):629-31.
2001: Koji Asano; Lawrence S Zisman; T Yoshikawa; Violetta V Headley; Michael R Bristow; J. David Port
Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes.
Journal of cardiovascular pharmacology 2001;37(6):678-91.
2001: J. David Port; Michael R Bristow
Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure.
Journal of molecular and cellular cardiology 2001;33(5):887-905.
2000: Burns C Blaxall; Lori D Dwyer-Nield; Alison K Bauer; Teresa J Bohlmeyer; Alvin M Malkinson; J. David Port
Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA binding protein (AUF1) and Hu antigen R (HuR), in neoplastic lung tissue.
Molecular carcinogenesis 2000;28(2):76-83.
2000: Edward M Gilbert; J. David Port
Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure.
Current cardiology reports 2000;2(3):225-32.
2000: Burns C Blaxall; A C Pellett; Steven C Wu; Aldo Pende; J. David Port
Purification and characterization of beta-adrenergic receptor mRNA-binding proteins.
The Journal of biological chemistry 2000;275(6):4290-7.
2000: Burns C Blaxall; J. David Port
Determination of mRNA stability and characterization of proteins interacting with adrenergic receptor mRNAs.
Methods in molecular biology (Clifton, N.J.) 2000;126():453-65.
1999: Aldo Pende; M Giacchè; L Castigliola; L Contini; Giancarlo Passerone; Mauro Patrone; J. David Port; G Lotti
Characterization of the binding of the RNA-binding protein AUF1 to the human AT(1) receptor mRNA.
Biochemical and biophysical research communications 1999;266(2):609-14.
1998: K D Mitchusson; Burns C Blaxall; Aldo Pende; J. David Port
Agonist-mediated destabilization of human beta1-adrenergic receptor mRNA: role of the 3' untranslated translated region.
Biochemical and biophysical research communications 1998;252(2):357-62.
1998: Michael R Bristow; J. David Port
Beta-adrenergic blockade in chronic heart failure.
Scandinavian cardiovascular journal. Supplement 1998;47():45-55.
1997: Koji Asano; DL Dutcher; J. David Port; Wayne A Minobe; K D Tremmel; Robert Roden; Teresa J Bohlmeyer; EW Bush; M J Jenkin; William T Abraham; Mary V Raynolds; Lawrence S Zisman; M Benjamin Perryman; Michael R Bristow
Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium.
Circulation 1997;95(5):1193-200.
1996: Aldo Pende; K D Tremmel; CT DeMaria; B C Blaxall; Wayne A Minobe; J A Sherman; John D Bisognano; Michael R Bristow; Gary Brewer; J. David Port
Regulation of the mRNA-binding protein AUF1 by activation of the beta-adrenergic receptor signal transduction pathway.
The Journal of biological chemistry 1996;271(14):8493-501.
1996: T Yoshikawa; J. David Port; Koji Asano; P Chidiak; M Bouvier; DL Dutcher; Robert Roden; Wayne A Minobe; K D Tremmel; Michael R Bristow
Cardiac adrenergic receptor effects of carvedilol.
European heart journal 1996;17 Suppl B():8-16.
1995: M White; R J Wiechmann; Robert Roden; M B Hagan; M M Wollmering; J. David Port; E Hammond; William T Abraham; Eugene E Wolfel; JoAnn Lindenfeld
Cardiac beta-adrenergic neuroeffector systems in acute myocardial dysfunction related to brain injury. Evidence for catecholamine-mediated myocardial damage.
Circulation 1995;92(8):2183-9.
1994: M White; Robert Roden; Wayne A Minobe; M F Khan; P Larrabee; M Wollmering; J. David Port; F Anderson; D Campbell; Arthur M Feldman
Age-related changes in beta-adrenergic neuroeffector systems in the human heart.
Circulation 1994;90(3):1225-38.
1993: Michael R Bristow; Wayne A Minobe; M V Raynolds; J. David Port; R Rasmussen; P E Ray; Arthur M Feldman
Reduced beta 1 receptor messenger RNA abundance in the failing human heart.
The Journal of clinical investigation 1993;92(6):2737-45.
1993: H M Farrukh; M White; J. David Port; D Handwerger; P Larrabee; J Klein; R A Roden; L Skerl; Dale G Renlund; Arthur M Feldman
Up-regulation of beta 2-adrenergic receptors in previously transplanted, denervated nonfailing human hearts.
Journal of the American College of Cardiology 1993;22(7):1902-8.
1992: J R Hadcock; J. David Port; M S Gelman; Craig C Malbon
Cross-talk between tyrosine kinase and G-protein-linked receptors. Phosphorylation of beta 2-adrenergic receptors in response to insulin.
The Journal of biological chemistry 1992;267(36):26017-22.
1992: J. David Port; L Y Huang; Craig C Malbon
Beta-adrenergic agonists that down-regulate receptor mRNA up-regulate a M(r) 35,000 protein(s) that selectively binds to beta-adrenergic receptor mRNAs.
The Journal of biological chemistry 1992;267(33):24103-8.
1992: J. David Port; C C Debellis; J Klein; G A Peeters; William H Barry; Michael R Bristow
Pharmacological characterization of chick and frog beta adrenergic receptors in primary cultures of myocardial cells.
The Journal of pharmacology and experimental therapeutics 1992;262(1):217-24.
1992: J. David Port; J R Hadcock; Craig C Malbon
Cross-regulation between G-protein-mediated pathways. Acute activation of the inhibitory pathway of adenylylcyclase reduces beta 2-adrenergic receptor phosphorylation and increases beta-adrenergic responsiveness.
The Journal of biological chemistry 1992;267(12):8468-72.
1992: Michael R Bristow; P Larrabee; Wayne A Minobe; Robert Roden; L Skerl; J Klein; D Handwerger; J. David Port; B Müller-Beckmann
Receptor pharmacology of carvedilol in the human heart.
Journal of cardiovascular pharmacology 1992;19 Suppl 1():S68-80.
1992: Michael R Bristow; P Larrabee; B Müller-Beckmann; Wayne A Minobe; Robert Roden; L Skerl; J Klein; D Handwerger; J. David Port
Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.
The Clinical investigator 1992;70 Suppl 1():S105-13.
1992: F L Anderson; J. David Port; B B Reid; P Larrabee; G Hanson; Michael R Bristow
Myocardial catecholamine and neuropeptide Y depletion in failing ventricles of patients with idiopathic dilated cardiomyopathy. Correlation with beta-adrenergic receptor downregulation.
Circulation 1992;85(1):46-53.
1992: F L Anderson; J. David Port; B B Reid; G Hanson; A C Kralios; Ray E Hershberger; Michael R Bristow
Effect of therapeutic dopamine administration on myocardial catecholamine and neuropeptide Y concentrations in the failing ventricles of patients with idiopathic dilated cardiomyopathy.
Journal of cardiovascular pharmacology 1992;20(5):800-6.
1991: Michael R Bristow; F L Anderson; J. David Port; L Skerl; Ray E Hershberger; P Larrabee; J B O'Connell; Dale G Renlund; K Volkman; J Murray
Differences in beta-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy.
Circulation 1991;84(3):1024-39.
1991: John K Hayes; K W Smith; J. David Port; W S Jordan
Comparison of tidal ventilation and high-frequency jet ventilation before and after cardiopulmonary bypass in dogs using two-dimensional transesophageal echocardiography.
Journal of cardiothoracic and vascular anesthesia 1991;5(4):320-6.
1991: H R Lee; Ray E Hershberger; J. David Port; R Rasmussen; Dale G Renlund; J B O'Connell; Edward M Gilbert; P C Mealey; K Volkman; R Menlove
Low-dose enoximone in subjects awaiting cardiac transplantation. Clinical results and effects on beta-adrenergic receptors.
The Journal of thoracic and cardiovascular surgery 1991;102(2):246-58.
1991: J R Hadcock; J. David Port; Craig C Malbon
Cross-regulation between G-protein-mediated pathways. Activation of the inhibitory pathway of adenylylcylclase increases the expression of beta 2-adrenergic receptors.
The Journal of biological chemistry 1991;266(18):11915-22.
1990: Michael R Bristow; Ray E Hershberger; J. David Port; Edward M Gilbert; A Sandoval; R Rasmussen; A E Cates; Arthur M Feldman
Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium.
Circulation 1990;82(2 Suppl):I12-25.
1990: J. David Port; Edward M Gilbert; P Larrabee; P Mealey; K Volkman; R Ginsburg; Ray E Hershberger; J Murray; Michael R Bristow
Neurotransmitter depletion compromises the ability of indirect-acting amines to provide inotropic support in the failing human heart.
Circulation 1990;81(3):929-38.
1989: Michael R Bristow; J. David Port; Ray E Hershberger; Edward M Gilbert; Arthur M Feldman
The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure.
European heart journal 1989;10 Suppl B():45-54.
1989: Michael R Bristow; Ray E Hershberger; J. David Port; Wayne A Minobe; R Rasmussen
Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium.
Molecular pharmacology 1989;35(3):295-303.